Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
December 02, 2024 07:00 ET
|
Autolus Therapeutics plc
High overall response rate: 76.6% of patients in the pivotal cohort achieved CR/Cri following treatment with obe-cel with a median follow-up of 20.3 monthsLow incidence of immune-related toxicity:...